Distinguished guest lecture AdBIOPRO: The role of continuous principles in the transformation of biomanufacturing

About Dr. Chetan Goudar
Chetan Goudar is an Executive Director of Process Development at Amgen (Thousand Oaks, CA, USA). His group is responsible for developing Drug Substance processes for all molecules in Amgen’s polymodal late-stage pipeline and enabling progression of these assets to commercial licensure. His group is also engaged in advancing drug substance manufacturing through the application of continuous principles across both synthetic and biologic modalities. Prior to joining Amgen in 2012, Chetan spent 13 years at Bayer HealthCare’s Process Development group in Berkeley, CA. He has a Ph.D. in Chemical & Biological Engineering from the University of British Columbia.

About Amgen
Founded in 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies (ranked twelfth world wide). To increase the likelihood of finding the best tool for the best target, Amgen has built an array of drug modalities that is unsurpassed in the biopharma industry. Their product portfolio and clinical pipeline contain ten distinct modalities.